Skip to search formSkip to main contentSkip to account menu

Pexastimogene-devacirepvec

Known as: JX-594, Thymidine Kinase-(-) Vaccinia-GM-CSF JX-594 Vaccine 
A thymidine kinase-deleted vaccinia virus expressing human GM-CSF (hGM-CSF) with oncolytic activity. Upon intratumoral or intravenous administration… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.
Advanced liver cancers and biliary cancers represent diseases with dismal prognosis because of frequent local invasion and… 
2014
2014
New frontier in liver cancer treatment: Oncolytic viral therapy
Oncolytic viruses and active immunotherapeutics have complementary mechanisms of action (MOA) that are both self amplifying in… 
Review
2013
Review
2013
Panorama From the Oncolytic Virotherapy Summit: 7th International Summit on Oncolytic Viral Therapeutics Quebec, Canada, 15-18 June 2013.
In June, the historical heart of Quebec City welcomed the 7th International Summit on Oncolytic Viral Therapeutics for an… 
2013
2013
Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with…
3608^ Background: Pexa-Vec is an EGFR-targeted vaccinia virus engineered to express granulocyte-macrophage colony stimulating… 
2012
2012
The Hitchhiker's Guide to Virotherapy
In contrast to most other cancer therapies, early research with oncolytic viruses (OV) tended to use direct or intratumoural… 
2012
2012
Phase IIb randomized trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who…
TPS4152 Background: JX-594 is a first-in-class targeted oncolytic poxvirus designed to selectively replicate in and destroy… 
2011
2011
Large drugs outdo small
volume 29 number 4 april 2011 nature biotechnology prepared by incubating (activating) a patient’s own antigen-presenting cells… 
2011
2011
131 JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IS WELL-TOLERATED AND EXHIBITS ANTI-TUMOR ACTIVITY IN PATIENTS WITH PRIMARY LIVER CANCER AND LIVER METASTASES
2010
2010
124 RANDOMIZED PHASE II CLINICAL TRIAL OF INTRATUMORAL INJECTION OF JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
2008
2008
Clinical proof-of-concept with JX-594, a novel targeted multi-mechanistic oncolytic poxvirus, in patients with refractory liver tumors
3573 Background: JX-594 is a first-in-class targeted oncolytic poxvirus designed to selectively replicate in and destroy cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)